Daniel E. Voth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel E. Voth has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Richard C. Kurten
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
9 shared publicationsAmanda L. Dragan
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
5 shared publicationsCaylin G. Winchell
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
5 shared publicationsJoseph G. Graham
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
5 shared publicationsKatelynn R. Brann
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
5 shared publicationsLaura J. MacDonald
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
4 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1895061
Breathing and burning: metabolic control of alveolar macrophages by intracellular bacterial pathogens
Alveolar macrophages (AMs) are the lung’s phagocytic immune sentinels, programmed to maintain homeostasis while defending against inhaled pathogens. AM metabolism is shaped by both developmental origin and the alveolar microenvironment. Embryonically-derived AMs populate the lungs early in life and develop into long-lived, self-renewing cells displaying lipid-centered, oxidative metabolism that restrains inflammation and preserves alveolar structure. When infection or injury disrupts homeostasis, circulating monocytes are recruited to the airspace and differentiate into monocyte-derived AMs, which adopt a glycolytic, short-lived, pro-inflammatory phenotype. Thus, differences in origin and transcriptional programming create two metabolically distinct AM populations with divergent roles in lung immunity. The intracellular bacterial pathogens Mycobacterium tuberculosis, Coxiella burnetii , Legionella pneumophila , and Francisella tularensis exploit these metabolic programs to facilitate intracellular growth and disease progression. By modulating glycolysis, remodeling mitochondria, manipulating lipid handling, or redirecting host metabolites, these pathogens evade immune insults and create growth niches. In this review, we discuss mechanisms by which AM metabolism shapes the tissue environment and pulmonary immunity, and we showcase intracellular pathogens to understand pro-bacterial reprogramming of AM metabolism.
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1895061
Open AccessBreathing and burning: metabolic control of alveolar macrophages by intracellular bacterial pathogens
Alveolar macrophages (AMs) are the lung’s phagocytic immune sentinels, programmed to maintain homeostasis while defending against inhaled pathogens. AM metabolism is shaped by both developmental origin and the alveolar microenvironment. Embryonically-derived AMs populate the lungs early in life and develop into long-lived, self-renewing cells displaying lipid-centered, oxidative metabolism that restrains inflammation and preserves alveolar structure. When infection or injury disrupts homeostasis, circulating monocytes are recruited to the airspace and differentiate into monocyte-derived AMs, which adopt a glycolytic, short-lived, pro-inflammatory phenotype. Thus, differences in origin and transcriptional programming create two metabolically distinct AM populations with divergent roles in lung immunity. The intracellular bacterial pathogens Mycobacterium tuberculosis, Coxiella burnetii , Legionella pneumophila , and Francisella tularensis exploit these metabolic programs to facilitate intracellular growth and disease progression. By modulating glycolysis, remodeling mitochondria, manipulating lipid handling, or redirecting host metabolites, these pathogens evade immune insults and create growth niches. In this review, we discuss mechanisms by which AM metabolism shapes the tissue environment and pulmonary immunity, and we showcase intracellular pathogens to understand pro-bacterial reprogramming of AM metabolism.
- Open Access
- 8 April 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (4) , e0282525
Guanylate-binding proteins balance iNOS/Arg-1 in myeloid cells during L. major infection and promote host defense to infection
Cutaneous leishmaniasis (CL) is a debilitating neglected tropical disease characterized by lesions that can range from self-healing to permanent disfiguration. A predominant Th1 response, which stimulates IFN-γ production, is crucial for parasite control during self-healing CL. While IFN-γ primarily activates macrophages to produce nitric oxide via inducible nitric oxide synthase (iNOS), leading to parasite control, it also activates other downstream pathways involved in cell autonomous immunity. One such pathway is the activation of guanylate-binding proteins (Gbps), a class of interferon-inducible GTPases. However, the role of Gbps during CL has been minimally explored. Utilizing RNA-Seq, we found that Leishmania major infection leads to the upregulation of several Gbps in C57BL/6 mice. In vitro studies using Gbp Chr3 knockout (KO) and C57BL/6 control mice reveal that bone marrow-derived macrophages from KO mice exhibit higher parasite burdens following IFN-γ treatment, independent of Gbp localization to the parasite. Single-cell RNA-Seq identifies macrophages as the primary expressers of Gbps during L. major infection in vivo. In vivo , Gbp Chr3 KO mice display increased disease severity and parasite load. Gbp Chr3 KO macrophages and monocytes show elevated ARG-1 and reduced iNOS expression, indicating a shift toward a parasite-permissive environment that supports parasite growth. These findings highlight a critical role for Gbps in immune-mediated control of CL. IMPORTANCE: Leishmania parasites cause cutaneous lesions that are often resistant to drug treatment, and no vaccine is currently available, highlighting the need to better understand host mechanisms that control infection. In this manuscript, we explore the role of guanylate-binding proteins (Gbps) in host macrophages during Leishmania major infection. We demonstrate that Gbps are critical for host defense both in vitro and in vivo . Notably, this protection is independent of Gbp localization to the parasite, revealing a novel aspect of Gbp biology. Instead, we find that differences in parasite burden and disease severity in Gbp-deficient mice are linked to altered activation of tissue macrophages and monocytes. Our findings suggest that Gbps coordinate inducible nitric oxide synthase expression in macrophages, the primary cells that house and control Leishmania parasites, and play a unique immunoregulatory role during infection.
- 8 April 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (4) , e0282525
Open AccessGuanylate-binding proteins balance iNOS/Arg-1 in myeloid cells during L. major infection and promote host defense to infection
Cutaneous leishmaniasis (CL) is a debilitating neglected tropical disease characterized by lesions that can range from self-healing to permanent disfiguration. A predominant Th1 response, which stimulates IFN-γ production, is crucial for parasite control during self-healing CL. While IFN-γ primarily activates macrophages to produce nitric oxide via inducible nitric oxide synthase (iNOS), leading to parasite control, it also activates other downstream pathways involved in cell autonomous immunity. One such pathway is the activation of guanylate-binding proteins (Gbps), a class of interferon-inducible GTPases. However, the role of Gbps during CL has been minimally explored. Utilizing RNA-Seq, we found that Leishmania major infection leads to the upregulation of several Gbps in C57BL/6 mice. In vitro studies using Gbp Chr3 knockout (KO) and C57BL/6 control mice reveal that bone marrow-derived macrophages from KO mice exhibit higher parasite burdens following IFN-γ treatment, independent of Gbp localization to the parasite. Single-cell RNA-Seq identifies macrophages as the primary expressers of Gbps during L. major infection in vivo. In vivo , Gbp Chr3 KO mice display increased disease severity and parasite load. Gbp Chr3 KO macrophages and monocytes show elevated ARG-1 and reduced iNOS expression, indicating a shift toward a parasite-permissive environment that supports parasite growth. These findings highlight a critical role for Gbps in immune-mediated control of CL. IMPORTANCE: Leishmania parasites cause cutaneous lesions that are often resistant to drug treatment, and no vaccine is currently available, highlighting the need to better understand host mechanisms that control infection. In this manuscript, we explore the role of guanylate-binding proteins (Gbps) in host macrophages during Leishmania major infection. We demonstrate that Gbps are critical for host defense both in vitro and in vivo . Notably, this protection is independent of Gbp localization to the parasite, revealing a novel aspect of Gbp biology. Instead, we find that differences in parasite burden and disease severity in Gbp-deficient mice are linked to altered activation of tissue macrophages and monocytes. Our findings suggest that Gbps coordinate inducible nitric oxide synthase expression in macrophages, the primary cells that house and control Leishmania parasites, and play a unique immunoregulatory role during infection.
- Open Access
Late-Stage Functionalization of the Rifamycin Core via Click Chemistry Toward New Antibacterial Derivatives
Antimicrobial resistance (AMR) threatens global health, particularly through the rise of multidrug-resistant tuberculosis (MDR-TB) and other critical bacterial infections such as methicillin-resistant Staphylococcus aureus (MRSA). Rifamycins remain frontline antibiotics but are increasingly undermined by resistance. Here, we introduce a click-enabled platform for the synthesis of C8-functionalized rifamycins, which can be converted in a single additional step into efficacious 3′-hydroxy-5′-aminobenzoxazinorifamycins (bxRifs) and enzymatically into 25-deacetylated rifamycins (deAcRifs), providing access to novel antibacterial scaffolds that expand beyond the scope of traditional C8 modifications. Accordingly, we establish a modular strategy for late-stage analog development of the complex natural product rifamycin S, wherein azido and alkyne functionalities are installed via tailored core chemistry and converted into 1,2,3-triazoles through copper(I)-catalyzed click chemistry. Another key feature of this work is the development of systematic HPLC purification methods, enabling the isolation of analytically pure compounds despite structural complexity. The resulting analogs exhibit distinct antibacterial profiles, notably against Gram-positive bacteria including MRSA and Streptococcus mutans, informing structure–activity relationships and offering a foundation for further optimization. This approach supports the rapid diversification of rifamycin scaffolds to combat the escalating threat of AMR, while also establishing a foundation for future discovery through bioorthogonal applications.
Open AccessLate-Stage Functionalization of the Rifamycin Core via Click Chemistry Toward New Antibacterial Derivatives
Antimicrobial resistance (AMR) threatens global health, particularly through the rise of multidrug-resistant tuberculosis (MDR-TB) and other critical bacterial infections such as methicillin-resistant Staphylococcus aureus (MRSA). Rifamycins remain frontline antibiotics but are increasingly undermined by resistance. Here, we introduce a click-enabled platform for the synthesis of C8-functionalized rifamycins, which can be converted in a single additional step into efficacious 3′-hydroxy-5′-aminobenzoxazinorifamycins (bxRifs) and enzymatically into 25-deacetylated rifamycins (deAcRifs), providing access to novel antibacterial scaffolds that expand beyond the scope of traditional C8 modifications. Accordingly, we establish a modular strategy for late-stage analog development of the complex natural product rifamycin S, wherein azido and alkyne functionalities are installed via tailored core chemistry and converted into 1,2,3-triazoles through copper(I)-catalyzed click chemistry. Another key feature of this work is the development of systematic HPLC purification methods, enabling the isolation of analytically pure compounds despite structural complexity. The resulting analogs exhibit distinct antibacterial profiles, notably against Gram-positive bacteria including MRSA and Streptococcus mutans, informing structure–activity relationships and offering a foundation for further optimization. This approach supports the rapid diversification of rifamycin scaffolds to combat the escalating threat of AMR, while also establishing a foundation for future discovery through bioorthogonal applications.
- 6 January 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (1) , e0196125
Coxiella burnetii Nine Mile II Δ cbu0533 as a suitable laboratory replacement strain
Coxiella burnetii is an intracellular bacterial pathogen that causes the disease Q fever. Both secretion of effector proteins by a type IVB secretion system and expression of lipopolysaccharide (LPS) are critical for C. burnetii virulence. The C. burnetii Nine Mile strain lineage is routinely used in laboratories, with Nine Mile I RSA493 (fully virulent) expressing phase I LPS, Nine Mile Crazy RSA514 (lightly attenuated) expressing intermediate LPS, and NMII RSA439 clone 4 (NMII, attenuated) expressing phase II LPS. NMII was exempted from the U.S. Centers for Disease Control and Prevention Federal Select Agent Program due to a genetic deletion predicted to prevent phase I LPS synthesis; however, recent findings demonstrated that NMII LPS elongation occurs in vivo and in vitro . These findings raise concerns regarding the suitability of NMII for manipulation at biosafety level-2 (BSL-2) containment. Here, we evaluated a mutant strain lacking the gene responsible for LPS elongation ( C. burnetii NMII Δ cbu0533 ) as an alternative strain for BSL-2 containment studies. Growth of wild-type NMII and NMII Δ cbu0533 in axenic media and macrophages was evaluated. Neither growth kinetics nor replication vacuole morphology significantly differed between strains. NMII Δ cbu0533 also prevented staurosporine-induced cell death, indicating that the mutant strain maintains the capacity to alter cell signaling events similar to wild-type C. burnetii . Cumulatively, these data reveal that C. burnetii NMII Δ cbu0533 is a suitable alternative to wild-type NMII in BSL-2 laboratory experiments that can be distributed to the field for use. IMPORTANCE: Attenuated C. burnetii NMII RSA439 clone 4 (NMII) expresses truncated lipopolysaccharide (LPS) and was long predicted to be unable to produce elongated LPS due to a large chromosomal deletion. As a result, this strain was exempted from the CDC Federal Select Agent Program’s regulation and is commonly used under biosafety level-2 laboratory conditions. Recently, it was shown that C. burnetii NMII LPS can elongate due to a mutation reversion in cbu0533 , resulting in increased virulence in guinea pigs. As a result, the previously exempted NMII strain is subject to regulation if the cbu0533 mutation reversion is present, posing concerns regarding laboratory use. Experiments described here provide a suitable alternative strain to address these concerns.
- 6 January 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (1) , e0196125
Coxiella burnetii Nine Mile II Δ cbu0533 as a suitable laboratory replacement strain
Coxiella burnetii is an intracellular bacterial pathogen that causes the disease Q fever. Both secretion of effector proteins by a type IVB secretion system and expression of lipopolysaccharide (LPS) are critical for C. burnetii virulence. The C. burnetii Nine Mile strain lineage is routinely used in laboratories, with Nine Mile I RSA493 (fully virulent) expressing phase I LPS, Nine Mile Crazy RSA514 (lightly attenuated) expressing intermediate LPS, and NMII RSA439 clone 4 (NMII, attenuated) expressing phase II LPS. NMII was exempted from the U.S. Centers for Disease Control and Prevention Federal Select Agent Program due to a genetic deletion predicted to prevent phase I LPS synthesis; however, recent findings demonstrated that NMII LPS elongation occurs in vivo and in vitro . These findings raise concerns regarding the suitability of NMII for manipulation at biosafety level-2 (BSL-2) containment. Here, we evaluated a mutant strain lacking the gene responsible for LPS elongation ( C. burnetii NMII Δ cbu0533 ) as an alternative strain for BSL-2 containment studies. Growth of wild-type NMII and NMII Δ cbu0533 in axenic media and macrophages was evaluated. Neither growth kinetics nor replication vacuole morphology significantly differed between strains. NMII Δ cbu0533 also prevented staurosporine-induced cell death, indicating that the mutant strain maintains the capacity to alter cell signaling events similar to wild-type C. burnetii . Cumulatively, these data reveal that C. burnetii NMII Δ cbu0533 is a suitable alternative to wild-type NMII in BSL-2 laboratory experiments that can be distributed to the field for use. IMPORTANCE: Attenuated C. burnetii NMII RSA439 clone 4 (NMII) expresses truncated lipopolysaccharide (LPS) and was long predicted to be unable to produce elongated LPS due to a large chromosomal deletion. As a result, this strain was exempted from the CDC Federal Select Agent Program’s regulation and is commonly used under biosafety level-2 laboratory conditions. Recently, it was shown that C. burnetii NMII LPS can elongate due to a mutation reversion in cbu0533 , resulting in increased virulence in guinea pigs. As a result, the previously exempted NMII strain is subject to regulation if the cbu0533 mutation reversion is present, posing concerns regarding laboratory use. Experiments described here provide a suitable alternative strain to address these concerns.
- Open Access
- 16 December 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (12) , e0028025
Control of human Q fever by vaccination: the journey to Q-VAX and beyond
Current vaccine development efforts encompass diverse and innovative approaches; however, studies with basic vaccines (e.g., whole cell inactivated) continue to inform these efforts. Perhaps the world’s most effective and durable human vaccine, the query (Q) fever vaccine known as Q-VAX, can trigger a severe post-vaccination hypersensitivity reaction, precluding its widespread deployment. The history of Q fever vaccine development serves as a rich example of the power of scientific collaboration, elegant experimentation, and the study of adverse post-vaccination events. Here, we review the history of Q fever vaccine development, profiling seminal studies while also relating this information to modern vaccine development efforts.
- 16 December 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (12) , e0028025
Open AccessControl of human Q fever by vaccination: the journey to Q-VAX and beyond
Current vaccine development efforts encompass diverse and innovative approaches; however, studies with basic vaccines (e.g., whole cell inactivated) continue to inform these efforts. Perhaps the world’s most effective and durable human vaccine, the query (Q) fever vaccine known as Q-VAX, can trigger a severe post-vaccination hypersensitivity reaction, precluding its widespread deployment. The history of Q fever vaccine development serves as a rich example of the power of scientific collaboration, elegant experimentation, and the study of adverse post-vaccination events. Here, we review the history of Q fever vaccine development, profiling seminal studies while also relating this information to modern vaccine development efforts.
- Open Access
Coxiella burnetii Strains Elicit Distinct Inflammatory Responses in Human Macrophages
Coxiella burnetii, the causative agent of human Q fever, subverts macrophage antimicrobial functions to establish an intracellular replicative niche. To better understand host–pathogen interactions, we investigated the transcriptional responses of human alveolar macrophages (hAMs) infected with virulent [NMI, G (Q212)], attenuated (NMII), and avirulent (Dugway) strains of C. burnetii. RNA sequencing indicated that all strains activated proinflammatory pathways, particularly IL-17 signaling, though the magnitude and nature of the response varied by strain. Infections with NMI, NMII or G (Q212) resulted in differential expression of roughly the same number of genes, while Dugway infection induced a stronger transcriptional response. Dugway and G (Q212) tended to polarize macrophages toward M1-like states, whereas responses to NMI and NMII were variable. Cytokine assays of NMII-infected THP-1 macrophages suggested the activation of IL-17 signaling, but only at later stages of infection, and single-cell RNA sequencing of NMII-infected THP-1 macrophages indicated heterogeneity in host response to infection, with distinct subpopulations exhibiting M1-like and M2-like inflammatory profiles. These findings highlight the complexity of macrophage response to C. burnetii and underscore the importance of strain-specific and cell-specific factors in shaping host immunity. Understanding these dynamics may inform the development of targeted therapies for Q fever.
Open AccessCoxiella burnetii Strains Elicit Distinct Inflammatory Responses in Human Macrophages
Coxiella burnetii, the causative agent of human Q fever, subverts macrophage antimicrobial functions to establish an intracellular replicative niche. To better understand host–pathogen interactions, we investigated the transcriptional responses of human alveolar macrophages (hAMs) infected with virulent [NMI, G (Q212)], attenuated (NMII), and avirulent (Dugway) strains of C. burnetii. RNA sequencing indicated that all strains activated proinflammatory pathways, particularly IL-17 signaling, though the magnitude and nature of the response varied by strain. Infections with NMI, NMII or G (Q212) resulted in differential expression of roughly the same number of genes, while Dugway infection induced a stronger transcriptional response. Dugway and G (Q212) tended to polarize macrophages toward M1-like states, whereas responses to NMI and NMII were variable. Cytokine assays of NMII-infected THP-1 macrophages suggested the activation of IL-17 signaling, but only at later stages of infection, and single-cell RNA sequencing of NMII-infected THP-1 macrophages indicated heterogeneity in host response to infection, with distinct subpopulations exhibiting M1-like and M2-like inflammatory profiles. These findings highlight the complexity of macrophage response to C. burnetii and underscore the importance of strain-specific and cell-specific factors in shaping host immunity. Understanding these dynamics may inform the development of targeted therapies for Q fever.
- 18 August 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (9) , e0143625
The intracellular agent of Q fever, Coxiella burnetii , alters human alveolar macrophage metabolism and mitochondrial physiology
Coxiella burnetii , the etiologic agent of Q fever, is a gram-negative intracellular bacterium that infects humans via contaminated aerosols typically while working with livestock. C. burnetii initially targets alveolar macrophages (AMs) to establish a growth niche within a phagolysosome-like compartment termed the Coxiella -containing vacuole (CCV). C. burnetii deploys a type IV secretion system (T4SS) to secrete effector proteins that control host cell functions to benefit the bacterium, orchestrating an immunosuppressive, pro-bacterial environment for replication to high numbers. Although multiple signaling pathways have been characterized in the context of C. burnetii infection, the role of host cell metabolic function in establishing favorable intracellular conditions is undefined. Using a primary human AM model, we show that C. burnetii maintains host oxidative phosphorylation (OXPHOS) at homeostasis in a T4SS-dependent manner. Inhibiting OXPHOS impairs CCV expansion, while preventing glycolysis and fatty acid oxidation does not alter vacuole development. Interestingly, mitochondria are shorter in infected cells, suggesting C. burnetii manipulates mitochondrial function to regulate host metabolism. Finally, endoplasmic reticulum (ER) stress regulates immunosuppressive macrophage activities, and C. burnetii regulates ER stress in a T4SS-dependent manner. Here, we show the involvement of protein kinase R-like endoplasmic reticulum kinase in regulating OXPHOS during infection. Collectively, our results demonstrate that C. burnetii engages human macrophage metabolic processes to establish a replication niche. IMPORTANCE: Coxiella burnetii causes human Q fever and is a potential bioterrorism threat. In humans, C. burnetii evades host cell killing and establishes a prolonged replication cycle within AMs, which is a critical step toward presentation of acute or chronic disease symptoms. While macrophage metabolism fuels antibacterial activity, we identified key metabolic processes that C. burnetii manipulates to sustain a pro-bacterial growth niche. Currently, few infection models capture C. burnetii interaction with disease-relevant human cells. Here, we used the established primary human AM infection system to characterize bacterial modulation of macrophage metabolism. Our findings advance understanding of C. burnetii -AM interactions and lay the foundation for future therapeutic exploration.
- 18 August 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (9) , e0143625
The intracellular agent of Q fever, Coxiella burnetii , alters human alveolar macrophage metabolism and mitochondrial physiology
Coxiella burnetii , the etiologic agent of Q fever, is a gram-negative intracellular bacterium that infects humans via contaminated aerosols typically while working with livestock. C. burnetii initially targets alveolar macrophages (AMs) to establish a growth niche within a phagolysosome-like compartment termed the Coxiella -containing vacuole (CCV). C. burnetii deploys a type IV secretion system (T4SS) to secrete effector proteins that control host cell functions to benefit the bacterium, orchestrating an immunosuppressive, pro-bacterial environment for replication to high numbers. Although multiple signaling pathways have been characterized in the context of C. burnetii infection, the role of host cell metabolic function in establishing favorable intracellular conditions is undefined. Using a primary human AM model, we show that C. burnetii maintains host oxidative phosphorylation (OXPHOS) at homeostasis in a T4SS-dependent manner. Inhibiting OXPHOS impairs CCV expansion, while preventing glycolysis and fatty acid oxidation does not alter vacuole development. Interestingly, mitochondria are shorter in infected cells, suggesting C. burnetii manipulates mitochondrial function to regulate host metabolism. Finally, endoplasmic reticulum (ER) stress regulates immunosuppressive macrophage activities, and C. burnetii regulates ER stress in a T4SS-dependent manner. Here, we show the involvement of protein kinase R-like endoplasmic reticulum kinase in regulating OXPHOS during infection. Collectively, our results demonstrate that C. burnetii engages human macrophage metabolic processes to establish a replication niche. IMPORTANCE: Coxiella burnetii causes human Q fever and is a potential bioterrorism threat. In humans, C. burnetii evades host cell killing and establishes a prolonged replication cycle within AMs, which is a critical step toward presentation of acute or chronic disease symptoms. While macrophage metabolism fuels antibacterial activity, we identified key metabolic processes that C. burnetii manipulates to sustain a pro-bacterial growth niche. Currently, few infection models capture C. burnetii interaction with disease-relevant human cells. Here, we used the established primary human AM infection system to characterize bacterial modulation of macrophage metabolism. Our findings advance understanding of C. burnetii -AM interactions and lay the foundation for future therapeutic exploration.
- 24 September 2024
- Published by Elsevier in Cellular Immunology
- Vol. 405-406, 104880
Embracing multiple infection models to tackle Q fever: A review of in vitro, in vivo, and lung ex vivo models
- 24 September 2024
- Published by Elsevier in Cellular Immunology
- Vol. 405-406, 104880
Embracing multiple infection models to tackle Q fever: A review of in vitro, in vivo, and lung ex vivo models
- 24 January 2023
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 91 (1) , e0019922
MicroRNAs Contribute to Host Response to Coxiella burnetii
MicroRNAs (miRNAs), a class of small noncoding RNAs, are critical to gene regulation in eukaryotes. They are involved in modulating a variety of physiological processes, including the host response to intracellular infections.
- 24 January 2023
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 91 (1) , e0019922
MicroRNAs Contribute to Host Response to Coxiella burnetii
MicroRNAs (miRNAs), a class of small noncoding RNAs, are critical to gene regulation in eukaryotes. They are involved in modulating a variety of physiological processes, including the host response to intracellular infections.
- Open Access
- 14 July 2022
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 12, 965554
Editorial: Obligate intracellular bacteria: Evasion and adaptative tactics shaping the host-pathogen interface
Editorial: Obligate intracellular bacteria: Evasion and adaptative tactics shaping the host-pathogen interface
- 14 July 2022
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 12, 965554
Open AccessEditorial: Obligate intracellular bacteria: Evasion and adaptative tactics shaping the host-pathogen interface
Editorial: Obligate intracellular bacteria: Evasion and adaptative tactics shaping the host-pathogen interface